Jeffrey Ha
@jeffreyha.bsky.social
Nephrologist
#cardiorenal #CKM syndrome
Postdoc @georgeinstitute.bsky.social @UNSWMedicine Sydney, Australia
@ajkd.bsky.social intern 22/23
#cardiorenal #CKM syndrome
Postdoc @georgeinstitute.bsky.social @UNSWMedicine Sydney, Australia
@ajkd.bsky.social intern 22/23
Reposted by Jeffrey Ha
🐇 Rapid #GDMT in HF with EF<50% (about 15 weeks) #medsky
Implementation= effective, safe, and associated with HF improvement
💊ARNi 52% vs 8%
💊Beta-blockers 78% vs 6.2%
💊MRA 98% vs 15.6%
💊#flozins 92% vs 6.2%
www.jacc.org/doi/full/10....
Implementation= effective, safe, and associated with HF improvement
💊ARNi 52% vs 8%
💊Beta-blockers 78% vs 6.2%
💊MRA 98% vs 15.6%
💊#flozins 92% vs 6.2%
www.jacc.org/doi/full/10....
April 8, 2025 at 7:48 PM
🐇 Rapid #GDMT in HF with EF<50% (about 15 weeks) #medsky
Implementation= effective, safe, and associated with HF improvement
💊ARNi 52% vs 8%
💊Beta-blockers 78% vs 6.2%
💊MRA 98% vs 15.6%
💊#flozins 92% vs 6.2%
www.jacc.org/doi/full/10....
Implementation= effective, safe, and associated with HF improvement
💊ARNi 52% vs 8%
💊Beta-blockers 78% vs 6.2%
💊MRA 98% vs 15.6%
💊#flozins 92% vs 6.2%
www.jacc.org/doi/full/10....
Reposted by Jeffrey Ha
Need weekend plans?
Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease
Happy reading!
bit.ly/4iMNijV
Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease
Happy reading!
bit.ly/4iMNijV
March 29, 2025 at 4:00 PM
Need weekend plans?
Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease
Happy reading!
bit.ly/4iMNijV
Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease
Happy reading!
bit.ly/4iMNijV
Round#2 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs ask are u CONVINCEd we have enough 💦 in the tank for HDF? Or less is more? It's a Brave New World with CAR-T cell therapy! Oxalate offenders - u can still have milk with your tea/coffee ☕😂 @nephmadness.bsky.social @nephjc.bsky.social
10/ ✍️you can read more about in the #nephmadness scouting report
ajkdblog.org/2025/03/01/n...
✍️and the commentary
ajkdblog.org/2025/03/10/n...
ajkdblog.org/2025/03/01/n...
✍️and the commentary
ajkdblog.org/2025/03/10/n...
#NephMadness 2025: Hemodialysis Region
Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025 Selection Committee Member: Mariana Murea @MarianaMurea Mariana Murea is an Associate Professor, nephrologist, and cl…
ajkdblog.org
March 21, 2025 at 8:51 PM
Round#2 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs ask are u CONVINCEd we have enough 💦 in the tank for HDF? Or less is more? It's a Brave New World with CAR-T cell therapy! Oxalate offenders - u can still have milk with your tea/coffee ☕😂 @nephmadness.bsky.social @nephjc.bsky.social
Reposted by Jeffrey Ha
Huge findings in Lancet. What does this mean? Aging of our organs is driving the development of diseases like COPD, CKD, heart failure, and liver failure. Interventions that slow biological aging could reduce the risk for many of the most common chronic diseases.
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
March 2, 2025 at 2:37 AM
Huge findings in Lancet. What does this mean? Aging of our organs is driving the development of diseases like COPD, CKD, heart failure, and liver failure. Interventions that slow biological aging could reduce the risk for many of the most common chronic diseases.
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Reposted by Jeffrey Ha
I hope the dialysis region of #Nephmadness sparks a generation of innovators.
A dialysis that is improving by leaps and bounds will lift patients, Nephrology, and medicine in its wake.
ajkdblog.org/2025/03/10/n...
A dialysis that is improving by leaps and bounds will lift patients, Nephrology, and medicine in its wake.
ajkdblog.org/2025/03/10/n...
#NephMadness 2025: Hemodialysis – The Future of Dialysis Personalization
Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025 Mariana Murea @MarianaMurea Mariana Murea is an Associate Professor, nephrologist, and clinician-scientist at Wake …
ajkdblog.org
March 11, 2025 at 5:35 AM
I hope the dialysis region of #Nephmadness sparks a generation of innovators.
A dialysis that is improving by leaps and bounds will lift patients, Nephrology, and medicine in its wake.
ajkdblog.org/2025/03/10/n...
A dialysis that is improving by leaps and bounds will lift patients, Nephrology, and medicine in its wake.
ajkdblog.org/2025/03/10/n...
Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social
March 11, 2025 at 9:28 AM
Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social
Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social
March 11, 2025 at 9:24 AM
Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social
Round#1 of #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of@nephmadness.bsky.social
March 11, 2025 at 9:13 AM
Round#1 of #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of@nephmadness.bsky.social
Reposted by Jeffrey Ha
A golden year of innovative kidney disease therapeutics 👩🔬🥼👨🔬🧪 #Kidneydisease #NephSky #CardioSky #cardiovascular #Nephropathy @natureportfolio.bsky.social 👇👇👇
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A golden year of innovative kidney disease therapeutics - Nature Reviews Nephrology
In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a soluble g...
www.nature.com
January 4, 2025 at 4:47 PM
A golden year of innovative kidney disease therapeutics 👩🔬🥼👨🔬🧪 #Kidneydisease #NephSky #CardioSky #cardiovascular #Nephropathy @natureportfolio.bsky.social 👇👇👇
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Jeffrey Ha
This is a must read for all #NephSky RCT readers (and RCT wannabe doers) from the Oxford trials folks in @ndt-era.bsky.social #OpenAccess
academic.oup.com/ndt/article/...
Table with core problems in RCTs and how to solve them
1/
academic.oup.com/ndt/article/...
Table with core problems in RCTs and how to solve them
1/
February 16, 2025 at 1:48 AM
This is a must read for all #NephSky RCT readers (and RCT wannabe doers) from the Oxford trials folks in @ndt-era.bsky.social #OpenAccess
academic.oup.com/ndt/article/...
Table with core problems in RCTs and how to solve them
1/
academic.oup.com/ndt/article/...
Table with core problems in RCTs and how to solve them
1/
Reposted by Jeffrey Ha
This is from a Bayer funded (but not Bayer influenced) @ndt-era.bsky.social supplement on trials and combination therapies in CKD
With really good reviews from experts incl @brendonneuen.bsky.social and many more
academic.oup.com/ndt/issue/40...
#NephSky
With really good reviews from experts incl @brendonneuen.bsky.social and many more
academic.oup.com/ndt/issue/40...
#NephSky
Volume 40 Issue Supplement_1 | Nephrology Dialysis Transplantation | Oxford Academic
An official journal of the European Renal Association - European Dialysis and Transplant Association. Publishes peer-reviewed original clinical and laboratory research across the full range of nephrol...
academic.oup.com
February 16, 2025 at 1:52 AM
This is from a Bayer funded (but not Bayer influenced) @ndt-era.bsky.social supplement on trials and combination therapies in CKD
With really good reviews from experts incl @brendonneuen.bsky.social and many more
academic.oup.com/ndt/issue/40...
#NephSky
With really good reviews from experts incl @brendonneuen.bsky.social and many more
academic.oup.com/ndt/issue/40...
#NephSky
@nephroseeker.medsky.social I'm excited for the HDF vs incremental HDx matchup!
March 1, 2025 at 9:29 PM
@nephroseeker.medsky.social I'm excited for the HDF vs incremental HDx matchup!
This recent survey in Australia New Zealand shows that #nephrologists and #cardiologists are split on the management of AF in advanced kidney disease. How do we provide multidisciplinary care to this high-risk group until more trial evidence is forthcoming?
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand
The results of this survey of nephrology and cardiology clinicians across Australia and New Zealand highlights inter- and intraspecialty heterogeneity in risk assessment and primary prevention of AF-...
onlinelibrary.wiley.com
February 27, 2025 at 6:01 AM
This recent survey in Australia New Zealand shows that #nephrologists and #cardiologists are split on the management of AF in advanced kidney disease. How do we provide multidisciplinary care to this high-risk group until more trial evidence is forthcoming?
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Reposted by Jeffrey Ha
📢 New Systematic Review & Meta-Analysis in
@kireports.bsky.social 📢
We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵
www.kireports.org/article/S246...
@kireports.bsky.social 📢
We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵
www.kireports.org/article/S246...
January 30, 2025 at 12:48 AM
📢 New Systematic Review & Meta-Analysis in
@kireports.bsky.social 📢
We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵
www.kireports.org/article/S246...
@kireports.bsky.social 📢
We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵
www.kireports.org/article/S246...
Reposted by Jeffrey Ha
The latest from my team in Nature Medicine.
We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).
By @Biostayan, Taeyoung Choi and me
A 🧵
www.nature.com/articles/s41...
We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).
By @Biostayan, Taeyoung Choi and me
A 🧵
www.nature.com/articles/s41...
Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine
An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...
www.nature.com
January 20, 2025 at 8:41 PM
The latest from my team in Nature Medicine.
We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).
By @Biostayan, Taeyoung Choi and me
A 🧵
www.nature.com/articles/s41...
We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).
By @Biostayan, Taeyoung Choi and me
A 🧵
www.nature.com/articles/s41...
Reposted by Jeffrey Ha
We treat patients, not lab results” can be augmented to “We treat patients, not P values.”
evidence.nejm.org/doi/full/10....
#MedSky @nejm.org @drmarthagulati.bsky.social @mmamas1973.bsky.social @cardioobdoc.bsky.social @shelleyzieroth.bsky.social
evidence.nejm.org/doi/full/10....
#MedSky @nejm.org @drmarthagulati.bsky.social @mmamas1973.bsky.social @cardioobdoc.bsky.social @shelleyzieroth.bsky.social
December 18, 2024 at 11:26 PM
We treat patients, not lab results” can be augmented to “We treat patients, not P values.”
evidence.nejm.org/doi/full/10....
#MedSky @nejm.org @drmarthagulati.bsky.social @mmamas1973.bsky.social @cardioobdoc.bsky.social @shelleyzieroth.bsky.social
evidence.nejm.org/doi/full/10....
#MedSky @nejm.org @drmarthagulati.bsky.social @mmamas1973.bsky.social @cardioobdoc.bsky.social @shelleyzieroth.bsky.social
Reposted by Jeffrey Ha
SAVE THE DATE: #NephMadness is just around the corner!
https://bit.ly/4frRAv3 (FREE)
@annaburgner.bsky.social @jrkott27.bsky.social @nephrosparks.bsky.social @kidneywars.bsky.social @nephmadness.bsky.social
https://bit.ly/4frRAv3 (FREE)
@annaburgner.bsky.social @jrkott27.bsky.social @nephrosparks.bsky.social @kidneywars.bsky.social @nephmadness.bsky.social
December 23, 2024 at 11:00 PM
SAVE THE DATE: #NephMadness is just around the corner!
https://bit.ly/4frRAv3 (FREE)
@annaburgner.bsky.social @jrkott27.bsky.social @nephrosparks.bsky.social @kidneywars.bsky.social @nephmadness.bsky.social
https://bit.ly/4frRAv3 (FREE)
@annaburgner.bsky.social @jrkott27.bsky.social @nephrosparks.bsky.social @kidneywars.bsky.social @nephmadness.bsky.social
Reposted by Jeffrey Ha
Are you using HIF-PHIs?
(I would love to try in predialysis and PD mostly, but the companies didn’t even bother coming to 🇨🇦)
(Disclosure we wrote this: evidence.nejm.org/doi/abs/10.1... mostly Jeff Ha and @sunilbadve.bsky.social )
(I would love to try in predialysis and PD mostly, but the companies didn’t even bother coming to 🇨🇦)
(Disclosure we wrote this: evidence.nejm.org/doi/abs/10.1... mostly Jeff Ha and @sunilbadve.bsky.social )
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease
Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta-analysis, we assessed long-term saf...
evidence.nejm.org
November 21, 2024 at 11:25 AM
Are you using HIF-PHIs?
(I would love to try in predialysis and PD mostly, but the companies didn’t even bother coming to 🇨🇦)
(Disclosure we wrote this: evidence.nejm.org/doi/abs/10.1... mostly Jeff Ha and @sunilbadve.bsky.social )
(I would love to try in predialysis and PD mostly, but the companies didn’t even bother coming to 🇨🇦)
(Disclosure we wrote this: evidence.nejm.org/doi/abs/10.1... mostly Jeff Ha and @sunilbadve.bsky.social )
Exciting to see so much change since I wrote my first review for MedicineToday as a trainee on CKD management. Fast forward a few yrs & I'm looking fwd to more evidence to implementing these pillars of therapy for Diabetic Kidney Disease! @catherinezheng.bsky.social @brendonneuen.bsky.social
A primer for any non-nephros (esp primary care colleagues) on the current world of diabetic kidney disease… big thanks to Amanda Mather, Sarah Roxburgh, and especially Jeff Ha and @brendonneuen.bsky.social for getting it to the finish line!
medicinetoday.com.au/mt/2024/dece...
medicinetoday.com.au/mt/2024/dece...
December 21, 2024 at 1:01 AM
Exciting to see so much change since I wrote my first review for MedicineToday as a trainee on CKD management. Fast forward a few yrs & I'm looking fwd to more evidence to implementing these pillars of therapy for Diabetic Kidney Disease! @catherinezheng.bsky.social @brendonneuen.bsky.social